Other
Hypoxia
53
Pipeline Programs↗
6
Active Trials↗
23
Companies Involved↗
Hypoxia is a moderately active landscape with 53 programs across 23 companies. The most active players are GSK, Johnson & Johnson, Auerbach Hematology Oncology Associates P C. 8 therapies are approved with 2 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical11
Phase 116
Phase 216
Phase 32
Analysis
Trial Status
52
clinical trials
Completed30 · 58%
Terminated7 · 13%
Unknown status5 · 10%
Recruiting4 · 8%
Withdrawn2 · 4%
Not yet recruiting2 · 4%
Other2 · 4%
Clinical Trials
Trial Activity
52 trials
The Efficacy of Remimazolam on Incidence of Hypoxia During Sedated Transvaginal Oocyte Retrieval: A Multicenter Randomized Controlled Trial.
Recruiting·—·N/A·NCT07335536·400 enrolled
Citicoline as Neuroprotector in Neonates Exposed to Hypoxia
Recruiting·—·Phase 3·NCT03949049·40 enrolled
Detection of Hypoxia in Human Thoracic Aorta Using Pimonidazole Hydrochloride
Completed·—·Phase 1·NCT03410420·9 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)